CYP2D6 genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian population

European Journal of Clinical Pharmacology

Volumn 68, Issue 5, 2012, Pages 637-644

  Dorado, Pedro ^a   Heras, Natalia ^b   Machín, Esther ^a   Hernández, Francisco ^c   Teran, Enrique ^b,d   LLerena, Adrián ^a,e  

^a UNIVERSITY OF EXTREMADURA   (Spain)

^b UNIVERSIDAD CENTRAL DEL ECUADOR   (Ecuador)

^c UNIVERSIDAD DE GUAYAQUIL   (Ecuador)

^d UNIVERSIDAD SAN FRANCISCO DE QUITO   (Ecuador)

^e HOSPITAL INFANTA CRISTINA   (Spain)

Author keywords

CYP2D6; Dextromethorphan; Ecuador; Pharmacogenetics

Indexed keywords

CYTOCHROME P450 2D6; DEXTROMETHORPHAN; DEXTRORPHAN;

ADULT; ARTICLE; CONTROLLED STUDY; CYP2D6 GENE; DRUG BLOOD LEVEL; DRUG HYDROXYLATION; ECUADORIAN; ETHNIC GROUP; FEMALE; GENE; GENE AMPLIFICATION; GENE DOSAGE; GENE DUPLICATION; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOMOZYGOTE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; POPULATION GENETICS; POPULATION RESEARCH; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ULTRAVIOLET RADIATION;

ADOLESCENT; ADULT; ALLELES; ANTITUSSIVE AGENTS; BIOTRANSFORMATION; CYTOCHROME P-450 CYP2D6; DEXTROMETHORPHAN; DEXTRORPHAN; ECUADOR; FEMALE; GENE DOSAGE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; HUMANS; HYDROXYLATION; MALE; POLYMORPHISM, GENETIC; YOUNG ADULT;

EID: 84864281440     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-1147-8     Document Type: Article

References (25)

1. Ingelman-Sundberg M (2005) Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5:6-13 (Pubitemid 40220611)
2. CYP2D6 allele nomenclature. Available at: http://www.cypalleles.ki.se/ cyp2d6.htm. Accessed 17 June 2011
3. LLerena A, Dorado P, Peñas-Lledó EM (2009) Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity. Pharmacogenomics 10:17-28
4. Frank D, Jaehde U, Fuhr U (2007) Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol 63:321-333 (Pubitemid 46399125)
5. Tamminga WJ, Wemer J, Oosterhuis B, Brakenhoff JP, Gerrits MG, de Zeeuw RA, de Leij LF, Jonkman JH (2001) An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19. Eur J Clin Pharmacol 57:143-146 (Pubitemid 32449135)
6. Dorado P, Suarez-Kurtz G, LLerena A (2007) Pharmacogenetics of cytochrome P450 in Hispanic populations. In: Suarez-Kurtz G (ed) Pharmacogenomics in admixed populations. Landes Bioscience, Austin, pp 60-74
7. LLerena A, Dorado P, Ramírez R, González I, Alvarez M, Peñas-Lledó EM, Pérez B, Calzadilla LR (2010) CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans. Pharmacogenomics J. doi:10.1038/tpj.2010.85
8. Dorado P, Cáceres M, Pozo-Guisado E, Wong ML, Licinio J, Llerena A (2005) Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use. Biotechniques 39[10 Suppl]:S571-S574
9. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS (2008) The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 83:234-242
10. Arias TD, Jorge LF, Lee D, Barrantes R, Inaba T (1988) The oxidative metabolism of sparteine in the Cuna Amerindians of Panama: absence of evidence for deficient metabolizers. Clin Pharmacol Ther 43:456-465
11. Sosa-Macías M, Elizondo G, Flores-Pérez C, Flores-Pérez J, Bradley-Alvarez F, Alanis-Bañuelos RE, Lares-Asseff I (2006) CYP2D6 genotype and phenotype in Amerindians of Tepehuano origin and Mestizos of Durango, Mexico. J Clin Pharmacol 46:527-536
12. Yeh GC, Tao PL, Ho HO, Lee YJ, Chen JY, Sheu MT (2003) Analysis of pharmacokinetic parameters for assessment of dextromethorphan metabolic phenotypes. J Biomed Sci 10:552-564 (Pubitemid 37025966)
13. Chládek J, Zimová G, Beránek M, Martí nková J (2000) In-vivo indices of CYP2D6 activity: comparison of dextromethorphan metabolic ratios in 4-h urine and 3-h plasma. Eur J Clin Pharmacol 56:651-657 (Pubitemid 32204484)
14. Muñoz S, Vollrath V, Vallejos MP, Miquel JF, Covarrubias C, Raddatz A, Chianale J (1998) Genetic polymorphisms of CYP2D6, CYP1A1 and CYP2E1 in the South-Amerindian population of Chile. Pharmacogenetics 8:343-351 (Pubitemid 28372328)
15. Sosa-Macías M, Dorado P, Alanis-Bañuelos RE, LLerena A, Lares-Asseff I (2010) Influence of CYP2D6 deletion, multiplication, -1584 C>G, 31 G>A and 2988 G>A gene polymorphisms on dextromethorphan metabolism among Mexican tepehuanos and mestizos. Pharmacology 86:30-36
16. Suarez-Kurtz G, Pena SD (2006) Pharmacogenomics in the Americas: the impact of genetic admixture. Curr Drug Targets 7:1649-1658 (Pubitemid 44873727)
17. Kohlrausch FB, Gama CS, Lobato MI, Belmonte-de-Abreu P, Gesteira A, Barros F, Carracedo A, Hutz MH (2009) Molecular diversity at the CYP2D6 locus in healthy and schizophrenic southern Brazilians. Pharmacogenomics 10:1457-1466
18. Isaza CA, Henao J, López AM, Cacabelos R (2000) Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population. Methods: Find Exp Clin Pharmacol 22:695-705 (Pubitemid 32216825)
19. Jorge LF, Eichelbaum M, Griese EU, Inaba T, Arias TD (1999) Comparative evolutionary pharmacogenetics of CYP2D6 in Ngawbe and Embera Amerindians of Panama and Colombia: role of selection versus drift in world populations. Pharmacogenetics 9:217-228 (Pubitemid 29359004)
20. Mendoza R, Wan YJ, Poland RE, Smith M, Zheng Y, Berman N, Lin KM (2001) CYP2D6 polymorphism in a Mexican American population. Clin Pharmacol Ther 70:552-560 (Pubitemid 34008413)
21. Luo HR, Gaedigk A, Aloumanis V, Wan YJ (2005) Identification of CYP2D6 impaired functional alleles in Mexican Americans. Eur J Clin Pharmacol 61:797-802 (Pubitemid 41722129)
22. Casner PR (2005) The effect of CYP2D6 polymorphisms on dextromethorphan metabolism in Mexican Americans. J Clin Pharmacol 45:1230-1235 (Pubitemid 41513045)
23. López M, Guerrero J, Jung-Cook H, Alonso ME (2005) CYP2D6 genotype and phenotype determination in a Mexican Mestizo population. Eur J Clin Pharmacol 61:749-754 (Pubitemid 41674261)
24. LLerena A, Edman G, Cobaleda J, Benítez J, Schalling D, Bertilsson L (1993) Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr Scand 87:23-28 (Pubitemid 23024862)
25. Estevez F, Giusti M, Parrillo S, Oxandabarat J (1997) Dextromethorphan O-demethylation polymorphism in the Uruguayan population. Eur J Clin Pharmacol 52:417-418 (Pubitemid 27341946)